Serine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Serine: From Open-Angle Glaucoma and Pulmonary Tuberculosis to Familial Visceral Myopathy
One-Sentence Summary
Serine is a proteinogenic amino acid, and in the knowledge graph it is linked to open-angle glaucoma and pulmonary tuberculosis. In Singapore it is marketed only as a component of parenteral nutrition products. The TxGNN model predicts it may be effective for familial visceral myopathy, but there are 0 clinical trials and 0 publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma; pulmonary tuberculosis (from the knowledge graph; Singapore label indication text is not available) |
| Predicted New Indication | Familial visceral myopathy |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 19 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Serine is a proteinogenic amino acid and is a component of amino acid infusion and parenteral nutrition products. Its original indications come from knowledge graph links rather than from approved label text.
The data compiled for this report establish no mechanistic link between serine and familial visceral myopathy, a rare smooth muscle disorder (for example, ACTG2-related). The very high TxGNN score (99.99%, overall rank 292) is a model output only, and no trials or publications support it. Because the prediction rests on the score alone, it should be treated as a hypothesis.
Other predictions show the same pattern. Examples are intestinal obstruction, intestinal pseudo-obstruction and several glaucoma types. The literature found for them was matched on the word "serine" or on unrelated conditions, such as the PRSS56 serine protease gene in angle-closure glaucoma or kinase mutations in Peutz-Jeghers syndrome. None of it evaluates serine as a treatment.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for familial visceral myopathy.
Singapore Market Information
Serine is marketed in Singapore as an ingredient of 19 valid single-ingredient registrations. The approved indication text is not available for these products. The five main authorizations are listed below.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16337P | AMINOVEN SOLUTION FOR INFUSION 15% | Infusion, solution | Not available |
| SIN11682P | AMINOVEN SOLUTION FOR INFUSION 5% | Injection | Not available |
| SIN11829P | AMINOVEN SOLUTION FOR INFUSION 10% | Injection | Not available |
| SIN06299P | NEPHROSTERIL FOR INTRAVENOUS INFUSION | Injection | Not available |
| SIN08352P | AMINOPLASMAL-15% INFUSION | Injection | Not available |
The other registrations include amino acid infusions, a peritoneal dialysis solution (Nutrineal) and lipid-containing parenteral nutrition emulsions (SmofKabiven, Nutriflex Omega, Oliclinomel). All are injectable or sterile solution forms, so the route of administration would need to be considered for any new indication.
Safety Considerations
Safety data from the package insert were not available. The knowledge graph links serine to contraindications in several disease areas. These links are not taken from label text and need verification against the package insert:
- Renal: kidney disease, chronic kidney disease, end-stage renal failure, nephrolithiasis, nephrocalcinosis
- Metabolic: diabetes mellitus, diabetic ketoacidosis, hypercalcemia, phosphorus metabolism disease
- Cardiovascular: heart disease, ventricular fibrillation, digitalis poisoning
- Neuropsychiatric: epilepsy, psychotic and anxiety disorders, substance abuse/dependence
- Other: vitamin B12 deficiency, megaloblastic anemia, sarcoidosis
No drug interaction records were found. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a high model score. There are no clinical trials, no relevant publications and no supported mechanistic link, so the evidence level is L5. The literature found is a keyword overlap with "serine" (genes and enzymes) and does not evaluate serine as a treatment. Safety data are also incomplete.
To proceed, the following is needed:
- Mechanism of action data for serine, and a plausible pathway link to visceral smooth muscle disease
- Package insert warnings and contraindications from HSA, to allow safety screening
- Singapore-approved indication text for the registered products
- Disease-specific preclinical or clinical evidence for serine in familial visceral myopathy
- A route and formulation compatibility assessment, because the registered products are all injectable or sterile solutions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.